Bone biology, osteoimmunology, aging, regeneration, cell therapy
About
Research investigates how inflammatory and epigenetic programs control osteoclast/osteoblast function across skeletal sites and aging, using single-cell genomics and imaging to inform targeted therapies for musculoskeletal regeneration. This work is complemented with studies focused on bone marrow regeneration using pre-clinical models and transcriptomic approaches evaluating human bone marrow specimens. We use single cell sequencing to evaluate biomarkers that associate with bone marrow regeneration, with an examination of the impact of age and/or sex within this context. A parallel line of research is exploring cellular and molecular mechanisms governing differences in bone marrow regeneration between men and women.
Partnering listings
Learn more
No Partnering listings yet
This innovator has not added partnering listings yet. For now, explore their publications, funding, and other profile details to identify promising topics to connect on.
No publications yet
This innovator hasn't added publications yet. In the meantime, you might want to explore their patents, funding, and other profile details.
Cellular Mechanisms of Age-Associated Cortical Bone Remodeling
National Institute of Health (NIH)
•
$375,100
•
2024
Characterization of Mandibular Osteoclast Progenitors during Physiological and Bone Healing
Osteoscience Foundation
•
$200,000
•
2023 - 2025
Epigenetic Reprogramming to Enhance Bone Regeneration in Type 2 Diabetes
Regenerative Medicine Minnesota
•
$250,000
•
2022 - 2024
Intradiscal Therapy: Mechanism of Action
Medtronic
•
$252,000
•
2019 - 2023
Functions of the PH-Domain Leucine Rich Protein Phosphatase (Phlpp) 1 in Osteoclasts
National Institute of Health (NIH)
•
$1,100,000
•
2017 - 2023
Phlpp Inhibitors for Articular Cartilage Repair and Regeneration
Regenerative Medicine Minnesota
•
$500,000
•
2015 - 2017
Epigenetic Regulation of Phlpp1 in Cartilage Development
NIH K01
•
$480,895
•
2014 - 2019
No patents yet
This innovator hasn't added patents yet. In the meantime, you might want to explore their publications, funding, and other profile details.